Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq ...

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Nektar Therapeutics’ hopes of rebuilding its battered business around lupus lie in tatters. The key phase 2 clinical trial of rezpegaldesleukin missed its primary endpoint, prompting partner Eli ...

Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after ...

Nektar.ai is meant to fill gaps and data leakage left by CRM tools with its no-code solution, which captures revenue activity data from email, calendar, chat and social channels like LinkedIn ...

Nektar confirmed the news in a separate release, announcing plans to push forward with rezpeg in atopic dermatitis. Rezpeb failed to meet expectations in a phase 2 lupus study back in February.

Nektar’s drug, bempegaldesleukin (bempeg) is an engineered cytokine, a signalling protein that prompts an immune response. Bempeg is Nektar’s version of a cytokine called interleukin-2 (IL-2).

In a recent filing with the Securities and Exchange Commission, Nektar Therapeutics (NASDAQ:NKTR) disclosed a significant change in its senior leadership team. The announcement comes as the ...

Nektar's stock was up 3 cents in after-hours trading Monday to $1.01. It's 52-week price has ranged from 60 cents to $5.18 per share, but it opened last year at $13.58.

Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointed Last Updated: April 17, 2023 at 6:03 p.m. ET First Published: April 17, 2023 at 5:54 p.m. ET Share ...

Nektar Therapeutics said that its experimental immunotherapy failed to provide additional benefit for patients with melanoma when given in combination with Bristol Myers Squibb’s Opdivo.